84.16

3.14% -2.73

After Hours: 84.50 0.34 +0.40%

Nektar Therapeutics (NKTR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Nektar Therapeutics stock is traded at $84.16, with a volume of 797.42K. It is down -3.14% in the last 24 hours and up +9.31% over the past month. Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Previous Close:

$86.89

Open:

$86.445

24h Volume:

797.42K

Relative Volume:

0.65

Market Cap:

$2.84B

Revenue:

$55.23M

Net Income/Loss:

$-164.08M

P/E Ratio:

-12.29

EPS:

-6.8461

Net Cash Flow:

$-208.68M

1W Performance:

+0.42%

1M Performance:

+9.31%

6M Performance:

+55.11%

1Y Performance:

+12,147%

1-Day Range:

$83.63

$87.56

1-Week Range:

$81.30

$88.10

52-Week Range:

$0.57

$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name

Nektar Therapeutics

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(415) 482-5300

Address

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Employee

Twitter

@nektarnews

Next Earnings Date

2026-05-14

Latest SEC Filings

NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NKTR Nektar Therapeutics	84.16	2.93B	55.23M	-164.08M	-208.68M	-6.8461
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Initiated	Wedbush	Neutral
Mar-17-26	Initiated	TD Cowen	Buy
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy
Jun-24-25	Reiterated	BTIG Research	Buy
Jun-24-25	Reiterated	H.C. Wainwright	Buy
Apr-11-25	Upgrade	Jefferies	Hold → Buy
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform
Jan-08-25	Initiated	B. Riley Securities	Buy
Dec-10-24	Initiated	H.C. Wainwright	Buy
Nov-04-24	Initiated	Piper Sandler	Overweight
Sep-30-24	Resumed	BTIG Research	Buy
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold
Feb-24-23	Downgrade	Jefferies	Hold → Underperform
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold
Apr-18-22	Downgrade	Goldman	Neutral → Sell
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-15-22	Downgrade	Mizuho	Buy → Neutral
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-14-22	Downgrade	Stifel	Buy → Hold
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy
Sep-10-21	Initiated	BofA Securities	Neutral
Jun-28-21	Upgrade	Stifel	Hold → Buy
May-18-21	Resumed	Goldman	Neutral
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold
Sep-14-20	Initiated	JP Morgan	Neutral
Jun-10-20	Downgrade	CFRA	Hold → Sell
May-12-20	Reiterated	H.C. Wainwright	Neutral
Apr-22-20	Initiated	The Benchmark Company	Buy
Mar-30-20	Upgrade	Goldman	Sell → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Feb-03-20	Upgrade	Mizuho	Neutral → Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-08-19	Downgrade	Goldman	Buy → Sell
Aug-09-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-09-19	Downgrade	Jefferies	Buy → Hold
Aug-09-19	Downgrade	Mizuho	Buy → Neutral
Mar-15-19	Initiated	SVB Leerink	Mkt Perform
Dec-13-18	Initiated	Goldman	Buy
Jun-11-18	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-18	Reiterated	H.C. Wainwright	Buy
Apr-20-18	Initiated	Seaport Global Securities	Buy
Apr-13-18	Resumed	Piper Jaffray	Overweight
Apr-06-18	Reiterated	Mizuho	Buy
Apr-02-18	Resumed	H.C. Wainwright	Buy

View All

Nektar Therapeutics Stock (NKTR) Latest News

May 05, 2026

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire

May 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

May 05, 2026

Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap - Seeking Alpha

May 05, 2026

NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - ChartMill

May 05, 2026

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics LawsuitNKTR - PR Newswire

May 05, 2026

May 04, 2026

NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - ChartMill

May 04, 2026

NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th - Scott Coop

May 04, 2026

Did Fast Track Rezpegaldesleukin Data and New Hires Just Shift Nektar Therapeutics' (NKTR) Investment Narrative? - simplywall.st

May 04, 2026

NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire

May 04, 2026

NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & - GlobeNewswire

May 04, 2026

NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com

May 04, 2026

Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - ChartMill

May 04, 2026

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

May 04, 2026

May 03, 2026

NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics ... - Caledonian Record

May 03, 2026

NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - GlobeNewswire Inc.

May 03, 2026

Why Nektar Therapeutics Stock Rocked it Today - MSN

May 03, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After New REZOLVE AA Data Funding And Phase 3 Plans - simplywall.st

May 03, 2026

May 02, 2026

How The Rezpegaldesleukin Story Is Recasting The Narrative For Nektar Therapeutics (NKTR) - Yahoo Finance

May 02, 2026

May 01, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

May 01, 2026